191P Preliminary biomarker and safety results of SQZ-PBMC-HPV at RP2D in monotherapy and combination with checkpoint inhibitors in HLA A*02+ patients with recurrent, locally advanced, or metastatic HPV16+ solid tumors

Abstract

Cancer vaccines strive to produce robust, antigen-targeted, T cell-mediated anti-tumor responses, but have struggled to induce tumor regression in patients. The Cell Squeeze® system achieves efficient antigen presentation by delivering target antigens directly into the cytosol of a patient’s PBMCs. SQZ-PBMC-HPV is an autologous cell vaccine that presents epitopes of HPV16 viral oncoproteins on HLA-A*02 to induce CD8 T cell activation. Monotherapy data showed tumor inflammation markers that may indicate correlation with clinical response motivating expansion of the monotherapy and combination with immune checkpoint inhibitors (ICIs).